ORKA
NASDAQOruka Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News25/Ratings11
News · 26 weeks62+56%
2025-12-282026-06-21
Mix4090d
- Insider17(43%)
- SEC Filings12(30%)
- Other6(15%)
- Offering3(8%)
- Earnings2(5%)
Latest news
25 items- INSIDERSenior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERDirector Dambkowski Carl sold $2,454,382 worth of shares (35,000 units at $70.13) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 38,743 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERSEC Form 4 filed by Director Dambkowski Carl4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Kulkarni Samarth4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Martin Christopher Nathan4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Ball Kristine M4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PRPhase 2 Data could Transform these Biotechs from Clinical Promise to Market ValidationDENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially
- PROruka Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceMENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026. Presentation DetailsDate: Wednesday, June 3rd, 2026Presentation Time: 3:45PM ET A webcast and replay of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka TherapeuticsOruka Therapeutics is de
- INSIDERDirector Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun exercised 7,833 shares at a strike of $28.80 and sold $607,806 worth of shares (10,290 units at $59.07) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 16,406 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $432,935 worth of shares (7,000 units at $61.85) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- PROruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001 MENLO PARK, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported first quarter 2026 financial results and provided a corporate upda
- SECSEC Form 10-Q filed by Oruka Therapeutics Inc.10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PRAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaSEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia
- PRHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyAgreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional targetSAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Oruka Therapeutics, Inc. (NASDAQ:ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.Under the agreement, Oruka has licensed Halozyme's Hypercon™ technology for use with ORKA‑001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon™ is an innovative microparticle technology that allows for
- INSIDERChief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $319,384 worth of shares (5,000 units at $63.88) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
ORKA FAQ
5 questionsWhere does ORKA stock trade?
Oruka Therapeutics Inc. (ORKA) is listed on NASDAQ.What sector and industry is ORKA in?
Oruka Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ORKA?
Oruka Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight on 2025-12-18. Recent price targets range from $2000.00 to $4900.00.What companies are similar to ORKA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare ORKA side-by-side with any of them on Quantisnow.How can I track ORKA on Quantisnow?
Quantisnow aggregates Oruka Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORKA to receive live email and push alerts on every new disclosure.